<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076880</url>
  </required_header>
  <id_info>
    <org_study_id>9016</org_study_id>
    <secondary_id>2012-A00962-41</secondary_id>
    <nct_id>NCT02076880</nct_id>
  </id_info>
  <brief_title>SLEEVEDIAB To Explore the Early and Late Metabolic Effects of Sleeve Gastrectomy in Obese Patients</brief_title>
  <acronym>SLEEVEDIAB</acronym>
  <official_title>Investigation of Endocrin-metabolic Modifications Related to Diabetes Improvement After Sleeve Gastrectomy in Severly Obese</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleeve gastrectomy is a restrictive procedure based on the removal of a large part of the&#xD;
      gastric fundus. According to a recent randomized study, weight loss and resolution of&#xD;
      diabetes are comparable to that obtained after gastric by-pass (79.7 % versus 80.3%), but&#xD;
      with a lower morbidity. The mechanisms involved in the rapid resolution of diabetes after&#xD;
      sleeve gastrectomy remain poorly understood, as no specific study in patients with type 2&#xD;
      diabetic obese are available. An increase in post- absorptive levels of Glucagon-like Peptide&#xD;
      1(GLP-1), Peptide YY(PYY) and insulin has been reported, but in non-diabetic subjects mostly.&#xD;
      The important caloric restriction in the early postoperative period indeed improves hepatic&#xD;
      insulin resistance, regardless of weight loss. Specific metabolic and hormonal effects of&#xD;
      this surgical procedure cannot be excluded.The aim of our study is to explore the early and&#xD;
      late metabolic effects of sleeve gastrectomy in severely obese patients with&#xD;
      non-insulin-treated type 2 diabetes. We will also evaluate insulin sensitivity, insulin&#xD;
      secretion and incretin effect. We will include 14 obese patients with type 2 diabetes,&#xD;
      considered eligible to bariatric surgery according to HAS criteria, and whose diabetes&#xD;
      treatment involves only metformin, sulfonylurea and glinides. They will be randomized to a&#xD;
      1-week caloric restriction period or no caloric restriction, immediately before surgery. Test&#xD;
      meals with dosages of blood glucose, insulin, C-peptide, adiponectin, leptin, GLP-1, PYY and&#xD;
      ghrelin will be performed before and after caloric restriction, and 1 week, 3 month, 6 month&#xD;
      and 12 month after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of area under the curve of post prandial glycemia</measure>
    <time_frame>Baseline to day 7 after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity, Change in insulin secretion, Change in incretins</measure>
    <time_frame>Blood samples at D-15, D-7 before surgery, D7, D80, D170, D350 after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Severe Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Arm with caloric restriction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will have, during 7 days before surgery, a caloric restriction of 1000 kcal per day compared to the usual food intake. They will be hospitalized during this period.&#xD;
Intervention: caloric restriction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm without caloric restriction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will not have a caloric restriction before surgery.&#xD;
Intervention: No caloric restriction</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Caloric restriction</intervention_name>
    <description>Caloric restriction of 1000 kcal per day compared to the usual food intake.&#xD;
usual breakfast of the patient (possibly limited in quantity)&#xD;
midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened</description>
    <arm_group_label>Arm with caloric restriction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No caloric restriction</intervention_name>
    <description>No change in eating habits to patients in this arm</description>
    <arm_group_label>Arm without caloric restriction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  Age between 18-65 years (inclusive)&#xD;
&#xD;
          -  Men or women receiving effective contraception, postmenopausal or sterile&#xD;
&#xD;
          -  type 2 diabetes treated with no drugs or oral anti-diabetic agents metformin,&#xD;
             sulfonylurea or glinides&#xD;
&#xD;
          -  Body mass index 35 kg / mÂ² or above&#xD;
&#xD;
          -  eligible to bariatric surgery according to HAS criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment of diabetes with GLP1 analogues, DPP-IV (dipeptidyl-peptidase IV) or insulin&#xD;
&#xD;
          -  Treatment with drugs that modify glucose homeostasis: glucocorticoids, anorexigens,&#xD;
             antihistaminics, psychotropic drugs especially serotonergic antidepressants (except&#xD;
             for the occasional use of a hypnotic or anxiolytic), atropine, laxatives, thyroid&#xD;
             hormones (with the exception of a substitution dose ensuring a stable euthyroid at&#xD;
             baseline), beta blockers, diuretics&#xD;
&#xD;
          -  Pregnancy, intention of being pregnant, breastfeeding.&#xD;
&#xD;
          -  Inability to understand the nature and aims of the study or to communicate with the&#xD;
             investigator- High probability of non&#xD;
&#xD;
          -  compliance with the protocol&#xD;
&#xD;
          -  Simultaneous participation in another trial&#xD;
&#xD;
          -  No affiliation to the French social security&#xD;
&#xD;
          -  Loss of personal capacity resulting in state protection&#xD;
&#xD;
          -  Deprivation of liberty by judicial or administrative decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence GALTIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence GALTIER, MD</last_name>
    <email>f-galtier@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric RENARD, PU-PH</last_name>
    <email>e-renard@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GALTIER Florence</last_name>
      <email>f-galtier@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>GALTIER Florence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Obesity</keyword>
  <keyword>Sleeve gastrectomy</keyword>
  <keyword>Insulin</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

